In our time, molecular targeted therapy plays a key role in the modern therapy of solid tumors. Of these modalities, in colorectal cancer monoclonal antibodies are introduced in routine use. In our article we provide an overview of the mechanism of action, place in treatment and efficacy of bevacizumab, an angiogenic inhibitor.
|Translated title of the contribution||Role of angiogenesis inhibitors in the treatment of colorectal cancer|
|Number of pages||6|
|Publication status||Published - Dec 1 2007|
ASJC Scopus subject areas